Loading...
XNASGRI
Market cap6mUSD
Dec 23, Last price  
0.75USD
1D
1.86%
1Q
63.87%
IPO
-91.22%
Name

GRI Bio Inc

Chart & Performance

D1W1MN
XNAS:GRI chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
11.83%
Rev. gr., 5y
%
Revenues
0k
00100,000000
Net income
-13m
L+80.67%
-4,312,646-3,774,563-4,856,000-9,380,000-7,216,000-13,037,000
CFO
0k
P
-2,371,004-2,883,735-3,706,000-8,312,000-7,135,0000
Dividend
Dec 29, 20080.0163 USD/sh
Earnings
Mar 26, 2025

Profile

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
IPO date
Feb 10, 2021
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT